Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / May / Robotic Phlebotomy Trial What the Patients Said
Clinical care Technology and innovation Research and Innovations Voices in the Community Workforce Trends

Robotic Phlebotomy Trial: What the Patients Said

Experts reflect on the future of phlebotomy in the light of new study results

By Helen Bristow 05/27/2026 Interview 6 min read
  • Full Article
  • Summary
  • Listen
  • Scorecard
  • Quiz
  • Top Thought Leaders

Share

Objective:

To evaluate the performance and patient acceptance of an autonomous robotic phlebotomy device (ARPD) in a clinical setting, specifically focusing on its effectiveness and patient feedback.

Key Findings:
  • The first-stick success rate of the ARPD was comparable to that of manual phlebotomists.
  • 90% of patients reported satisfaction with the robotic blood draw in terms of comfort, though younger patients were more hesitant about the technology.
  • Younger patients were more reserved about robotic blood draws compared to middle-aged and older patients, raising questions about their acceptance of automation.
Interpretation:

The ARPD shows promise in improving phlebotomy efficiency and patient experience, with high acceptance rates among patients.

Limitations:
  • The ARPD is not suitable for young children or patients unable to cooperate, which limits its applicability in certain demographics.
  • Some patients expressed concerns about automation and job replacement, highlighting the need for clear communication about the role of technology in healthcare.
Conclusion:

The study indicates a positive reception of robotic phlebotomy among patients, suggesting potential for broader implementation in clinical settings, particularly in addressing staffing challenges.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Helen Bristow

Combining my dual backgrounds in science and communications to bring you compelling content in your speciality.

More Articles by Helen Bristow

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Breathing New Life into Diagnostics
Technology and innovation
Breathing New Life into Diagnostics

January 22, 2024

6 min read

Jonathan Edgeworth on how metagenomics could transform testing for respiratory infections

Opening a Window into Brain Trauma
Technology and innovation
Opening a Window into Brain Trauma

January 18, 2024

4 min read

Raman spectroscopy shows promise as the first point-of-care diagnostic device for TBI

Molecular Spectacular
Technology and innovation
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

Cracking Colon Cancer
Technology and innovation
Cracking Colon Cancer

January 25, 2024

1 min read

How a new clinically approved AI-based tool enables rapid microsatellite instability detection

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.